Drug Use Investigation Of Bosutinib For Cml (Post Marketing Commitment Plan)

Trial Profile

Drug Use Investigation Of Bosutinib For Cml (Post Marketing Commitment Plan)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BLF
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Mar 2017 Planned End Date changed from 1 Sep 2023 to 22 Sep 2023.
    • 22 Mar 2017 Planned primary completion date changed from 1 Sep 2023 to 22 Sep 2023.
    • 20 Mar 2017 Planned number of patients changed from 659 to 1.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top